Description

The global induced pluripotent stem cells market is poised to grow by US$ 1.9 billion during 2022-2028, progressing at a CAGR of 8.6% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for induced pluripotent stem cells. The global induced pluripotent stem cells market is segmented on the basis of function, reprogramming method, method, application, and region. By function, the global induced pluripotent stem cells market has been segmented into cell analysis, cell culture, cell differentiation, cellular and molecular bioengineering, cellular reprogramming. In 2021, the cell differentiation segment made up the largest share of revenue generated by the induced pluripotent stem cells market. Based upon reprogramming method, the global induced pluripotent stem cells market is categorized into integrated, non-integrated. The non-integrated segment was the largest contributor to the global induced pluripotent stem cells market in 2021. On the basis of method, the global induced pluripotent stem cells market has been segmented into DNA-based, protein-based, RNA-based, small molecule-based. The DNA-based segment is estimated to account for the largest share of the global induced pluripotent stem cells market. By application, the global induced pluripotent stem cells market has been segmented into academic research, drug development, regenerative medicine. The drug development segment held the largest share of the global induced pluripotent stem cells market in 2021 and is anticipated to hold its share during the forecast period. Geographically, the global induced pluripotent stem cells market is segmented into Asia Pacific, Europe, USA, Rest of the World (RoW).

The global induced pluripotent stem cells market is highly competitive. The report also includes the profiles of leading companies such as Bio-Techne Corporation, BlueRock Therapeutics LP, Bristol Myers Squibb (BMS), Cell Signaling Technology Inc., Corning Incorporated, FUJIFILM Cellular Dynamics Inc., InvivoGen Limited, Lonza Group AG, Merck KGaA, Promega Corporation, Qiagen N.V., STEMCELL Technologies Inc., Thermo Fisher Scientific Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the induced pluripotent stem cells market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Function: cell analysis, cell culture, cell differentiation, cellular and molecular bioengineering, cellular reprogramming
Reprogramming method: integrated, non-integrated
Method: DNA-based, protein-based, RNA-based, small molecule-based
Application: academic research, drug development, regenerative medicine
Region: Asia Pacific, Europe, USA, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global induced pluripotent stem cells market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Induced pluripotent stem cells market overview
Part 3. Market breakdown by function
– Cell analysis
– Cell culture
– Cell differentiation
– Cellular and molecular bioengineering
– Cellular reprogramming
Part 4. Market breakdown by reprogramming method
– Integrated
– Non-integrated
Part 5. Market breakdown by method
– DNA-based
– Protein-based
– RNA-based
– Small molecule-based
Part 6. Market breakdown by application
– Academic research
– Drug development
– Regenerative medicine
Part 7. Market breakdown by region
– Asia Pacific
– Europe
– USA
– Rest of the World (RoW)
Part 8. Key companies
– Bio-Techne Corporation
– BlueRock Therapeutics LP
– Bristol Myers Squibb (BMS)
– Cell Signaling Technology, Inc.
– Corning Incorporated
– FUJIFILM Cellular Dynamics, Inc.
– InvivoGen Limited
– Lonza Group AG
– Merck KGaA
– Promega Corporation
– Qiagen N.V.
– STEMCELL Technologies Inc.
– Thermo Fisher Scientific Inc.
About StrategyHelix
Disclaimer